About Sientra (NASDAQ:SIEN)
Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$36.54 million
Price / Sales5.54
Price / CashN/A
Book Value$1.42 per share
Price / Book7.25
Return on Equity-107.35%
Return on Assets-55.62%
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) posted its earnings results on Tuesday, March, 13th. The medical instruments supplier reported ($0.92) EPS for the quarter, missing the Zacks' consensus estimate of ($0.71) by $0.21. The medical instruments supplier earned $11.10 million during the quarter, compared to analysts' expectations of $11.90 million. Sientra had a negative net margin of 175.22% and a negative return on equity of 107.35%. The company's quarterly revenue was up 70.8% on a year-over-year basis. During the same period last year, the business earned ($0.43) earnings per share. View Sientra's Earnings History.
Where is Sientra's stock going? Where will Sientra's stock price be in 2018?
5 brokerages have issued 1 year price objectives for Sientra's stock. Their predictions range from $11.00 to $18.00. On average, they expect Sientra's stock price to reach $13.75 in the next twelve months. View Analyst Ratings for Sientra.
Are investors shorting Sientra?
Sientra saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,243,433 shares, an increase of 38.8% from the January 31st total of 1,616,684 shares. Based on an average trading volume of 322,601 shares, the days-to-cover ratio is currently 7.0 days. Currently, 16.4% of the shares of the stock are sold short.
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Quanterix (QTRX), Antares Pharma (ATRS), Endologix (ELGX), Oxford Immunotec Global (OXFD), Utah Medical Products (UTMD), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), RTI Surgical (RTIX), Evolus (EOLS), Rockwell Medical (RMTI), Quotient (QTNT), Chimerix (CMRX), Pulse Biosciences (PLSE), Fluidigm (FLDM), T2 Biosystems (TTOO), Cogentix Medical (CGNT), Aceto (ACET) and Cytosorbents (CTSO).
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Jeffrey M. Nugent, Chairman of the Board, Chief Executive Officer (Age 70)
- Patrick F. Williams, Chief Financial Officer, Senior Vice President, Treasurer (Age 44)
- Charles Huiner, Chief Operating Officer, Senior Vice President - Corporate Development and Strategy (Age 45)
- Nicholas J. Simon III, Lead Independent Director (Age 63)
- Keith J. Sullivan, Director (Age 59)
- R. Scott Greer, Independent Director (Age 58)
- Timothy Haines, Independent Director (Age 59)
- Kevin C. O'Boyle, Independent Director
Has Sientra been receiving favorable news coverage?
News headlines about SIEN stock have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sientra earned a news impact score of 0.13 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 44.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Sientra's major shareholders?
Sientra's stock is owned by a number of of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (5.50%), Goldman Sachs Group Inc. (3.97%), BlackRock Inc. (3.91%), Bamco Inc. NY (2.53%), Senzar Asset Management LLC (2.50%) and Driehaus Capital Management LLC (1.59%). View Institutional Ownership Trends for Sientra.
Which institutional investors are selling Sientra stock?
SIEN stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, PEAK6 Investments L.P., Renaissance Technologies LLC, Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, Bamco Inc. NY and Bank of New York Mellon Corp. View Insider Buying and Selling for Sientra.
Which institutional investors are buying Sientra stock?
SIEN stock was purchased by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, X Square Capital LLC, BlackRock Inc., Vident Investment Advisory LLC, Two Sigma Advisers LP, Creative Planning, Two Sigma Investments LP and Deutsche Bank AG. View Insider Buying and Selling for Sientra.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $10.30.
How big of a company is Sientra?
Sientra has a market capitalization of $199.58 million and generates $36.54 million in revenue each year. The medical instruments supplier earns $-64,020,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis. Sientra employs 200 workers across the globe.
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (SIEN)MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sientra (NASDAQ:SIEN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.80||3.00||2.80||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$13.75||$15.00||$13.75||$13.67|
|Price Target Upside: ||33.50% upside||45.21% upside||13.68% downside||8.64% upside|
Sientra (NASDAQ:SIEN) Consensus Price Target History
Sientra (NASDAQ:SIEN) Analyst Ratings History
(Data available from 3/20/2016 forward)
Sientra (NASDAQ:SIEN) Earnings History and Estimates Chart
Sientra (NASDAQ SIEN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/13/2018||Q4 2017||($0.71)||($0.92)||$11.90 million||$11.10 million||View||Listen|
|11/7/2017||Q3 2017||($0.68)||($0.74)||$10.54 million||$9.80 million||View||N/A|
|8/9/2017||Q2 2017||($0.59)||($0.55)||$6.97 million||$8.20 million||View||Listen|
|5/9/2017||Q1 2017||($0.49)||($0.61)||$5.98 million||$7.50 million||View||Listen|
|3/14/2017||Q4 2016||($0.52)||($0.43)||$6.76 million||$6.50 million||View||N/A|
|11/8/2016||Q3 2016||($0.55)||($0.55)||$5.60 million||$6.53 million||View||N/A|
|8/9/2016||Q216||($0.51)||($0.56)||$4.80 million||$6.20 million||View||N/A|
|5/5/2016||Q1||($0.74)||($0.66)||$2.40 million||$1.47 million||View||N/A|
|3/9/2016||Q4||($0.56)||($1.57)||$1.00 million||$1.50 million||View||N/A|
|8/12/2015||Q215||($0.33)||($0.20)||$13.84 million||$14.20 million||View||Listen|
|5/13/2015||Q115||($0.40)||($0.23)||$11.50 million||$12.40 million||View||Listen|
|3/11/2015||Q414||($0.35)||($0.34)||$10.70 million||$12.12 million||View||Listen|
Sientra (NASDAQ:SIEN) Earnings Estimates
2018 EPS Consensus Estimate: ($2.73)
2019 EPS Consensus Estimate: ($2.25)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Sientra (NASDAQ:SIEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Sientra (NASDAQ SIEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 77.38%
Sientra (NASDAQ SIEN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/12/2015||Orbimed Advisors Llc||Major Shareholder||Sell||287,891||$5.98||$1,721,588.18|| |
|10/9/2015||Orbimed Advisors Llc||Major Shareholder||Sell||666,609||$7.18||$4,786,252.62|| |
|10/6/2015||Orbimed Advisors Llc||Major Shareholder||Sell||193,000||$8.71||$1,681,030.00|| |
|10/1/2015||Orbimed Advisors Llc||Major Shareholder||Sell||101,898||$10.24||$1,043,435.52|| |
|9/28/2015||Orbimed Advisors Llc||Major Shareholder||Sell||150,908||$10.58||$1,596,606.64|| |
|10/29/2014||Llp Abingworth||Major Shareholder||Buy||495,000||$15.00||$7,425,000.00|| |
Sientra (NASDAQ SIEN) News Headlines
|Edited Transcript of SIEN earnings conference call or presentation 13-Mar-18 8:30pm GMT|
finance.yahoo.com - March 18 at 9:18 AM
|Zacks Investment Research Upgrades Sientra (SIEN) to Buy|
www.americanbankingnews.com - March 17 at 2:48 PM
|Sientra (SIEN) Upgraded to Hold by ValuEngine|
www.americanbankingnews.com - March 17 at 11:58 AM
|Sientra (SIEN) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - March 17 at 11:16 AM
|Analysts Offer Predictions for Sientra Inc's Q1 2018 Earnings (SIEN)|
www.americanbankingnews.com - March 16 at 7:56 AM
|Sientra (SIEN) Price Target Cut to $18.00 by Analysts at Canaccord Genuity|
www.americanbankingnews.com - March 14 at 11:12 AM
|Sientra (SIEN) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS|
www.americanbankingnews.com - March 14 at 9:48 AM
|Sientra Reports Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 13 at 6:26 PM
|ValuEngine Lowers Sientra (SIEN) to Sell|
www.americanbankingnews.com - March 11 at 9:46 PM
|Sientra Inc (SIEN) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - March 7 at 11:45 AM
|Investors Purchase Large Volume of Sientra Call Options (SIEN)|
www.americanbankingnews.com - March 6 at 8:24 AM
|Senzar Asset Management LLC Boosts Holdings in Sientra Inc (SIEN)|
www.americanbankingnews.com - March 5 at 3:44 PM
|Short Interest in Sientra Inc (SIEN) Expands By 38.8%|
www.americanbankingnews.com - March 4 at 1:40 AM
|Sientra® to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, March 13, 2017|
finance.yahoo.com - March 2 at 5:11 PM
|Sientra (SIEN) Receives "Buy" Rating from William Blair|
www.americanbankingnews.com - March 1 at 12:54 PM
|X Square Capital LLC Takes $2.23 Million Position in Sientra Inc (SIEN)|
www.americanbankingnews.com - February 27 at 2:34 PM
|Sientra (SIEN) Downgraded to "Sell" at ValuEngine|
www.americanbankingnews.com - February 25 at 6:35 PM
|Sientra Launches New miraDry fresh™ Protocol for the miraDry® System at American Academy of Dermatology Annual Meeting|
finance.yahoo.com - February 24 at 4:48 PM
|Head to Head Contrast: Align Technology (ALGN) & Sientra (SIEN)|
www.americanbankingnews.com - February 23 at 3:26 PM
|The global tissue expanders market is anticipated to reach USD 1.5 billion by 2025|
www.prnewswire.com - February 22 at 4:55 PM
|Sientra (SIEN) Stock Rating Lowered by Lake Street Capital|
www.americanbankingnews.com - February 21 at 1:42 PM
|BRIEF-Sientra Says Co Enters Into Agreement With Stifel, Nicolaus & Co Inc|
www.reuters.com - February 21 at 9:24 AM
|Sientra Inc (SIEN) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - February 10 at 7:50 AM
|Sientra (SIEN) Upgraded to "Hold" at ValuEngine|
www.americanbankingnews.com - February 4 at 1:48 PM
|FY2019 Earnings Forecast for Sientra Inc Issued By William Blair (SIEN)|
www.americanbankingnews.com - February 2 at 3:42 PM
|Critical Analysis: Sientra (SIEN) vs. Neogen (NEOG)|
www.americanbankingnews.com - January 31 at 9:12 PM
|BRIEF-Sientra Provides Update On FDA Review Of U.S. Manufacturing Facility|
www.reuters.com - January 31 at 9:31 AM
|Sientra® Provides Update on FDA Review of U.S. Manufacturing Facility|
finance.yahoo.com - January 30 at 4:23 PM
|Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - January 25 at 4:22 PM
|Sientra (SIEN) Upgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - January 24 at 1:22 PM
|Sientra (SIEN) Upgraded by Stifel Nicolaus to "Buy"|
www.americanbankingnews.com - January 20 at 9:02 PM
|Sientra Inc (SIEN) Given Average Rating of "Hold" by Brokerages|
www.americanbankingnews.com - January 16 at 8:00 AM
|Zacks: Brokerages Expect Sientra Inc (SIEN) Will Announce Earnings of -$0.68 Per Share|
www.americanbankingnews.com - January 16 at 3:08 AM
|BRIEF-Sientra Inc Files For Mixed Shelf Of Upto $150 Million|
www.reuters.com - January 9 at 11:03 AM
|Sientra Announces Preliminary Unaudited Fourth Quarter 2017 Revenue - GlobeNewswire (press release)|
globenewswire.com - January 8 at 3:51 PM
|Sientra Announces Preliminary Unaudited Fourth Quarter 2017 Revenue|
finance.yahoo.com - January 8 at 8:50 AM
|Sientra (SIEN) Earns Buy Rating from Canaccord Genuity|
www.americanbankingnews.com - January 5 at 1:34 PM
|Sientra (SIEN) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - January 1 at 10:38 AM
|Head-To-Head Comparison: Sientra (SIEN) vs. SurModics (SRDX)|
www.americanbankingnews.com - December 30 at 11:13 AM
|Comparing Halyard Health (HYH) and Sientra (SIEN)|
www.americanbankingnews.com - December 23 at 1:24 AM
|Sientra Inc (SIEN) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - December 22 at 8:50 AM
|Interested In Sientra Inc (NASDAQ:SIEN)? Here’s What Its Recent Track-Record Looks Like|
finance.yahoo.com - December 19 at 11:16 AM
|Sientra (SIEN) Rating Increased to Hold at BidaskClub|
www.americanbankingnews.com - December 16 at 12:02 PM
|Traders Buy Large Volume of Sientra Put Options (SIEN)|
www.americanbankingnews.com - December 14 at 4:10 AM
|Sientra (SIEN) Rating Lowered to Sell at BidaskClub|
www.americanbankingnews.com - December 7 at 10:32 PM
|ETFs with exposure to Sientra, Inc. : December 7, 2017|
finance.yahoo.com - December 7 at 3:53 PM
|Sientra, Inc. :SIEN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017|
finance.yahoo.com - December 1 at 6:26 PM
|Sientra, Inc. (SIEN) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - November 27 at 7:46 AM
|Sientra's (SIEN) CEO Jeff Nugent on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 9 at 1:21 PM
|BRIEF-Sientra's total net sales for Q3 2017 were $9.8 million|
www.reuters.com - November 9 at 1:21 PM
Sientra (NASDAQ:SIEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sientra (NASDAQ:SIEN) Income Statement, Balance Sheet and Cash Flow Statement
Sientra (NASDAQ SIEN) Stock Chart for Tuesday, March, 20, 2018